BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

GTx, Inc. (GTXI) Announces Presentation on Enobosarm's Improvement in Physical Function in Cancer Patients With Both Low and Normal Testosterone Levels


6/25/2012 10:36:26 AM

MEMPHIS, Tenn.--(BUSINESS WIRE)--GTx, Inc. (Nasdaq: GTXI) announced today that in a Phase IIb clinical study of enobosarm, there was significantly improved physical function after 16 weeks of treatment, compared to placebo, in both hypogonadal (low testosterone) and eugonadal (normal testosterone) subjects. The study met its primary endpoint of absolute change in total lean body mass (muscle) compared to placebo after 16 weeks of treatment. The data were reported by Adrian Dobs, M.D., M.H.S., professor of medicine and oncology, and Vice-Chair of the Department of Medicine, Faculty Development at The Johns Hopkins University Medical School, during the 2012 Annual Meeting of The Endocrine Society (ENDO 2012). Enobosarm is currently being evaluated in two pivotal Phase III clinical trials.

Read at BioSpace.com


GTx, Inc.
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->